Med-IQ
Browse CME/CE Courses
Need Help?
CME Information
|
Browse CME/CE
Activity Progress Icon
Activity Progress
Abstract Icon
Abstract
Education
Earn Credit Information Icon 0 out of 1 modules complete
Certificate Awarded
Clinical Advances in Diagnostics and Therapies for FGFR-Altered Cancer: November 2021 Updates: Part Four

Clinical Advances in Diagnostics and Therapies for FGFR-Altered Cancer: November 2021 Updates: Part Four

Webcast
Continue to Course
Save
Online Course | Specialties: Family Medicine, Internal Medicine, Oncology
Released: 12/20/2021
|
Expires: 12/19/2022
|
Max Credits: 1.5
Continue to Course Read Abstract
Need Help?

Faculty
Sameek Roychowdhury, MD, PhD 
Associate Professor, Department of Internal Medicine 
Division of Medical Oncology 
Medical Director, CLIA?Certified Cancer Genomics Laboratory 
The Ohio State University, James Cancer Hospital and Comprehensive Cancer Center 
Columbus, OH 
 
Carlos L. Arteaga, MD 
Professor of Medicine
Director, UTSW Harold C. Simmons Comprehensive Cancer Center
Dallas, TX
 
James M. Cleary, MD, PhD 
Clinical Investigator, Hale Family Center for Pancreatic Cancer Research 
Department of Medical Oncology, Dana-Farber Cancer Institute 
Assistant Professor of Medicine, Harvard Medical School 
Boston, MA

Activity Planners
Julie Blum, PhD
Director, Clinical Content
Med-IQ
Baltimore, MD

Samantha Gordon, MS
Accreditation Manager 
Med-IQ
Baltimore, MD

Amy Sison
Director of CME
Med-IQ
Baltimore, MD

Kathryn Schaefer, MSN, RN, CPHRM
Associate Director, Education Quality and Compliance
Med-IQ
East Lansing, MI 

Learning Objectives
Upon completion, participants should be able to:

  • Summarize the current and potential role of FGFR inhibitors in cancer treatment with regard to mechanism of action, efficacy, and safety
  • Discuss future research and translational approaches on FGFR signaling from basic science to clinical studies
  • Integrate the latest clinical evidence with FGFR inhibitors into practice as these agents become available or in the context of clinical trial enrollment for patients with cancer

Target Audience
This activity is intended for oncology professionals including physicians, physician assistants, nurse practitioners, nurses, and researchers.

Statement of Need
Advances with technology and an increased understanding of the molecular pathways that drive oncogenesis have led to the development of novel therapies targeting fibroblast growth factor receptor (FGFR) aberrations in multiple tumor types. Several FGFR inhibitors are producing profound and durable responses in cancer treatment. An FGFR inhibitor recently gained FDA approval in the treatment of urothelial cancer, and other approvals are anticipated. Optimizing the clinical use of FGFR inhibitors will depend on the appropriate selection of patients who are most likely to benefit from these agents as well as the selection of the optimal FGFR-targeting agent, taking into account the selectivity of the agents, efficacy and toxicity profiles, and the design and implementation of novel strategies to overcome resistance mechanisms and further improve response rates. To that end, developing a clear understanding of the emerging research and the evolving landscape of FGFR inhibitors in various tumor types is needed to effectively optimize the use these agents in clinical practice.

Providership Satement
Provided by Med-IQ. 

Accreditation/Designation Statements
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Med-IQ designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 
Med-IQ is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
 
This nursing activity has been approved for up to 1.5 contact hours.
 
Physician assistants and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.

Instructions to Receive Credit
To receive credit, read the introductory CE material, watch the webcast, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.
 
Initial Release Date: December 20, 2021
Expiration Date: December 19, 2022
Estimated Time to Complete This Activity: 1 hour and 30 minutes

Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 24 months that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.

Off-label/unapproved drug uses or products are mentioned within this activity.

Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation. 

Carlos Arteaga, MD 
Consulting fees/advisory boards: Arvinas, AstraZeneca, Athenex, Inc., Daiichi Sankyo, Co., Ltd., Immunomedics, Inc., Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, OrigiMed, Sanofi-aventis U.S. Inc., Taiho Pharmaceutical Co, Ltd.

Contracted research: Lilly USA, LLC, Pfizer, Inc.
Ownership interest (stocks/stock options – excluding mutual funds): Provista
 
James M. Cleary, MD, PhD 
Consulting fees/advisory boards: Syros Pharmaceuticals, Inc.
Contracted research: AbbVie Inc., AstraZeneca, Bayer Healthcare, Bristol-Myers Squibb, Esperas Pharma Inc., F. Hoffman-La Roche, GlaxoSmithKline, Merck & Co., Inc., Merus

Sameek Roychowdhury, MD, PhD 
Consulting fees/advisory boards: Incyte Corporation, Merck & Co., Inc.  

The peer reviewers and activity planners have no financial relationships to disclose. 
  
Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, Med-IQ has a policy to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
 
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity
 
Contact Information        
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email info@med-iq.com.

System Requirements

Desktop

Mobile

  • Operating system - Med-IQ supports the current operating system, plus two prior releases:
    • Android (eg, Samsung Galaxy)
    • Apple (eg, iPhone/iPad)
  • Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
    • Android (Chrome)
    • Apple (Safari)

Applications & Software

For technical assistance, please refer to our Support Manual.

Disclaimer
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy notice, please visit: www.med-iq.com/privacy-statement/.

Complimentary CE
This activity is available free of charge to participants.

Acknowledgement of Commercial Support
This activity is supported by an educational grant from QED Therapeutics.

Copyright
Copyrighted
Abstract

Here are the key takeaways from this activity. Deeper insights and evidence, plus an opportunity to receive credit, are available at the "Continue" button below.

  • Until recently, there were no approved options after first-line treatment and no routinely used, FDA-approved targeted therapies for cholangiocarcinoma1
  • A randomized, phase 2 trial recently demonstrated a modest survival benefit of FOLFOX compared with best supportive care in cholangiocarcinoma; however, more effective therapies still need to be developed2
  • Other recent phase 2 studies of pemigatinib and infigratinib showed 35% and 23% increases, respectively, in the overall response rate in patients with locally advanced or metastatic cholangiocarcinomas with FGFR2 mutations; additionally, FGFR INDELs in cholangiocarcinoma have been shown to be sensitive to the FGFR inhibitor Debio-13473
  • Only a fraction of ER+/FGFR1-amplified breast cancers are FGFR1 dependent and, thus, likely to respond to FGFR1 inhibitors4
  • FGFR1 amplification is associated with resistance to estrogen deprivation in patients with breast cancer and correlated with early progression on CDK4/6 inhibitors, as shown in the PALOMA-3 trial5

View reference list.

Click “Continue” to proceed through this activity and/or receive credit. 

By clicking "Continue," you confirm that you have reviewed the CME information.

Continue

Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

COPYRIGHTED. Republication or redistribution of Med‑IQ content, including by framing, is prohibited without prior written consent. Med‑IQ shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.